Timothy Keutzer is COO at Spero Therapeutics, Inc. (SPRO). They have made 8 open-market trades across 1 company since 2023, most recently 2026-02-06.
CIK 0001798155
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| SPRO | 742,506 | $787K |
Shares reported on the most recent Form 4, priced at the 2026-02-09 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SPRO | SELL | 2026-02-06 | 2026-02-09 | $2.36 | $44K | -4.2% | +7.9% | +6.7% |
| SPRO | SELL | 2026-02-02 | 2026-02-05 | $2.17 | $101K | +0.9% | +0.4% | +9.5% |
| SPRO | SELL | 2025-08-28 | 2025-09-03 | $1.97 | $3K | -9.6% | -1.4% | +5.8% |
| SPRO | SELL | 2025-02-05 | 2025-02-05 | $0.78 | $44K | -8.2% | -12.9% | -34.0% |
| SPRO | SELL | 2024-08-27 | 2024-08-29 | $1.35 | $3K | -2.9% | -2.9% | -18.1% |
| SPRO | SELL | 2024-02-02 | 2024-02-05 | $1.36 | $42K | +4.8% | +18.6% | +14.5% |
| SPRO | SELL | 2023-08-28 | 2023-08-30 | $1.26 | $2K | -10.3% | -16.6% | -20.0% |
| SPRO | SELL | 2023-02-02 | 2023-02-03 | $1.86 | $6K | -4.3% | -18.7% | +0.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.